

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* ZELDIS JEROME B		2. Issuer Name and Ticker or Trading Symbol BioSig Technologies, Inc. [BSGM]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> 10% Owner <input type="checkbox"/> Other (specify below)	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/21/2019		
C/O BIOSIG TECHNOLOGIES, INC., 12424 WILSHIRE BLVD., SUITE 745			4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
(Street) LOS ANGELES, CA 90025					
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/21/2019		C		13,334	A	\$ 3.75	82,043	D	
Common Stock	05/21/2019		A		3,804 <u>(1)</u>	A	\$ 7.44 <u>(1)</u>	85,847	D	
Common Stock	05/22/2019		M		20,000	A	\$ 3.4	105,847	D	
Common Stock	05/22/2019		M		1,097	A	\$ 6.85	106,944	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date				
Series C Preferred Stock	\$ 3.75	05/21/2019		C		50	<u>(2)</u>	<u>(2)</u>	Common Stock	13,334	\$ 0	0	D	
Options to Purchase Common Stock	\$ 3.4	05/22/2019		M		20,000	12/22/2016	12/22/2026	Common Stock	20,000	\$ 0	0	D	
Warrants to Purchase Common Stock	\$ 6.85	05/22/2019		M		1,097	08/17/2018	08/17/2021	Common Stock	1,097	\$ 0	0	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

ZELDIE JEROME B C/O BIOSIG TECHNOLOGIES, INC. 12424 WILSHIRE BLVD., SUITE 745 LOS ANGELES, CA 90025	X			
--	---	--	--	--

Signatures

/s/ Kenneth L. Londoner, attorney-in-fact <small>Signature of Reporting Person</small>		05/22/2019 <small>Date</small>
---	--	-----------------------------------

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Each share of the Series C Preferred Stock is entitled to a nine percent (9%) annual dividend on the \$1,000 per share stated value. The dividends accrued and became payable in cash or, at the Issuer's option and subject to the satisfaction of certain conditions, in pay-in-kind shares. Such cumulative dividends were payable quarterly, commencing on September 30, 2013, thereafter quarterly on December 31, March 31, June 30 and September 30, and on the conversion date. The reporting person's 50 shares of Series C Preferred Stock were converted on May 21, 2019, and the Issuer elected to pay the accrued dividends in pay-in-kind shares. Pursuant to the terms of the Series C Preferred Stock and using the price calculated pursuant to the terms of the Series C Preferred Stock, the reporting person received 3,804 shares of common stock as a payment-in-kind dividend upon conversion of 50 shares of Series C Preferred Stock owned by the reporting person on the conversion date.
- (1) The Series C Preferred Stock could be converted at any time at the option of the holder into shares of common stock at a conversion price of \$3.75 per share. The Series C Preferred Stock had no expiration date.
- (2) The Series C Preferred Stock could be converted at any time at the option of the holder into shares of common stock at a conversion price of \$3.75 per share. The Series C Preferred Stock had no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.